Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal update from its Phase 3 CAPTIVATE trial. The company, which specializes in "next-generation" complement inhibitors, announced that its lead candidate, claseprubart (DNTH103), met early responder [...]
As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster" that could sustain their independence. Today, Argenx (NASDAQ: ARGX) has effectively ended that search, cementing its status as a global biopharmaceutical powerhouse. Following its full-year 2025 earnings [...]
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a significant 15% stock surge, a move driven by clinical validation of its diversified "Vant" model. This recent rally—pushing shares toward a yearly high of $24.21—is primarily [...]
Immunovant stock drops 10% despite meeting Q2 FY2026 earnings estimates. The sell-off is driven by investor reaction to clinical pipeline updates for its anti-FcRn therapies.
Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company.
Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus to its lead asset, IMVT-1402.
